Autoinjectors Market (By Therapy: Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, Other Therapies; By Type: Disposable, Reusable; By Route of Administration: Subcutaneous, Intramuscular; By Type of Molecule: Monoclonal Antibody, Peptide, Protein, Small Molecule; By End-User: Hospitals & Clinics, Ambulatory Care Settings) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030


The global autoinjectors market size was exhibited at USD 46.8 billion in 2021 and is expected to extend to around USD 247.3 billion by 2030, registering at a CAGR of 20.32% over the forecast period from 2022 to 2030.

Autoinjectors Market Size 2022 To 2030

Key Takeaways:

  • North America was accounted highest revenue share of over 41.6% in 2021.
  • The Asia-Pacific market is growing at a CAGR of 18.9% from 2022 to 2030.
  • By end user, the home care segment has highest revenue share of 53% in 2021 and it is growing at a CAGR of 18.5% over the forecast period.
  • The disposable autoinjectors segment is growing at a CAGR of 18.7% from 2022 to 2030.
  • The anaphylaxis segment is growing at a CAGR of 18.5% from 2022 to 2030.

Growth Factors

The growth of the autoinjectors market is majorly driven by the increasing prevalence of targeted therapies, the growing occurrence of anaphylaxis, increasing consumer preferences for self-administration of drugs, advantages of usability, the rising number of regulatory body approvals, the easy accessibility of generic autoinjectors, government assistance, and advantageous reimbursements, and advancement of technology and others.

Additionally, according to a study published in 2019 by the European Journal of Allergy and Clinical Immunology, global Overall anaphylaxis in children occurs at a rate of 1 to 761 per 100,000 person-years, while food-related anaphylaxis occurs at a rate of 1 to 77 per 100,000 person-years. Anaphylaxis is a severe, potentially fatal allergic reaction caused due to food, latex, Hymenoptera stings and medicines. Thus, the growing incidence of anaphylaxis is propelling the market growth.

Anaphylaxis is treated with epinephrine as the first line of defense. For anaphylaxis, pharmaceutical companies are developing technologically enhanced epinephrine autoinjectors (EAIs). This technological advancement includes portable devices, innovative designs, autoinjectors with two auto-injectable doses in one device, temperature-stabilized autoinjectors and longer shelf life for epinephrine, gadgets that alert patients when a dose has been administered effectively and others. Therefore, such technological advancements is expected to fuel the demand for autoinjectors in the upcoming years contributing towards the market growth.

Scope of the Autoinjectors Market

Report Coverage Details
Market Size in 2022 USD 56.31 Billion
Market Size by 2030 USD 247.3 Billion
Growth Rate from 2022 to 2030 CAGR of 20.32%
Largest Market North America
Fastest Growing Market Asia-Pacific 
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Therapy, Type, Route of Administration, Type of Molecule, End-User, and Geography
Companies Mentioned AbbVie Inc., Mylan, Eli Lilly and Company, Ypsomed, Amgen, Becton, Dickinson and Company, Antares Pharma, GlaxoSmithKline plc, Johnson & Johnson, Teva Pharmaceutical, Merck KGaA


Segments Insights

Therapy Insights

Based on therapy, the autoinjector market is divided into rheumatoid arthritis, anaphylaxis, diabetes, multiple sclerosis, multiple sclerosis, and others. In 2021, the rheumatoid arthritis segment accounted for the lion market share. This was majorly attributable to its high rate of occurrence globally. According to the CDC, arthritis, rheumatoid arthritis, gout, lupus, and fibromyalgia affect an estimated 43.7 million individuals (22.7 percent of the total population) in the United States each year. Thus, the growing incidence of rheumatoid arthritis propelling the demand for autoinjectors ultimately contributing towards the growth of the market.

Type Insights

By type, the autoinjectors market is bifurcated into disposable and reusable autoinjectors. In 2021, the disposable autoinjectors segment accounted for the highest share in the autoinjectors market.

Autoinjectors Market Share, By Type, 2021 (%)

This is attributable to its ease of use and the existence of a built-in glass syringe (which eliminates the need to manually load a glass syringe), making it the most popular autoinjectors among patients with poor dexterity or visual impairments.

Route of Administration Insights

Based on the route of administration, the market is divided into subcutaneous and intramuscular. The subcutaneous segment accounted for the highest market share and is anticipated to be the fastest growing segment during the forecast period.

Autoinjectors Market Share, By Route of Administration, 2021 (%)

This is mainly attributable to the rising number of product acceptance by the regulatory bodies for chronic disease treatment.

End-User Insights

Based on end users, the autoinjectors market is segregated into hospitals & clinics, ambulatory care settings and home care settings. The home care settings segment holds the largest market share in the year 2021, owing to the speedy growth in the aging population globally coupled with the growing demand for low-cost drug administration.

Autoinjectors Market Share, By Region, 2021 (%)

Regions Revenue Share in 2021 (%)
North America 41.6%
Asia Pacific 22.5%
Europe 26.5%
Latin America 5%
MEA 4.4%


Regional Insights

North America is the largest market for autoinjectors market, followed by Europe and the Asia Pacific. Factors such as the increased incidence of anaphylaxis and the availability of advantageous reimbursements are driving growth in the North American market. Furthermore, the United States and Canada are developed economies with high consumer awareness and the use of modern devices such as autoinjectors, which is favorable to market expansion. Other microeconomic elements that contribute to market growth include increased healthcare expenditures, a high rate of affordability and an improving regulatory environment.

Asia-pacific is anticipated to be the fastest growing market during the forecast year. The huge diabetic population and rising healthcare expenditures in Asia Pacific region are driving the market expansion which in turn is attracting a number of key autoinjector device manufacturers to this region. The key players are increasingly expanding their presence in the Asia Pacific market in a variety of ways, including opening sales offices and forming partnerships with local pharmaceutical companies.

Segments Covered in the Report

(Note*: We offer reports based on sub-segments as well. Kindly, let us know if you are interested)

By Therapy

  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Diabetes
  • Anaphylaxis
  • Other Therapies

By Type

  • Disposable
  • Reusable

By Route of Administration

  • Subcutaneous
  • Intramuscular

By Type of Molecule

  • Monoclonal Antibody
  • Peptide
  • Protein
  • Small Molecule

By End-User

  • Home Care Settings
  • Hospitals & Clinics
  • Ambulatory Care Settings

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

What is the current size of autoinjectors market?
The global autoinjectors market size was accounted at USD 46.8 billion in 2021 and it is expected to reach around USD 247.3 billion by 2030.
What will be the CAGR of global autoinjectors market?
The global autoinjectors market is poised to grow at a CAGR of 20.32% from 2022 to 2030.
Who are the prominent players operating in the autoinjectors market?
The major players operating in the autoinjectors market are AbbVie Inc., Mylan, Eli Lilly and Company, Ypsomed, Amgen, Becton, Dickinson and Company, Antares Pharma, GlaxoSmithKline plc, Johnson & Johnson, Teva Pharmaceutical, Merck KGaA
Which are the driving factors of the autoinjectors market?
Increasing prevalence of targeted therapies, increasing consumer preferences for self-administration of drugs and rising number of regulatory body approvals these are driving the growth of the autoinjectors market.
Which region will lead the global autoinjectors market?
North America region will lead the global autoinjectors market during the forecast period 2022 to 2030.
  • Report Code:2288
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:October 2022

PROCEED TO BUY

   USD 4900
   USD 6900
   USD 8900

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample